Hedgehog (HH) signaling is important in the pathogenesis of several malignancies. Recently, we described that HH signaling proteins are commonly expressed in diffuse large B-cell lymphoma (DLBCL); however, the functional role of HH pathway in DLBCL has not been explored. Here, we assessed the possibility that HH pathway activation contributes to the survival of DLBCL. We found that HH signaling inhibition induces predominantly cell-cycle arrest in DLBCL cells of germinal center (GC) B-cell type, and apoptosis in DLBCL cells of activated B-cell (ABC) type. Apoptosis after HH signaling inhibition in DLBCL cells of ABC type was associated with downregulation of BCL2; however HH inhibition was not associated with BCL2 downregulation in DLBCL of GC type. Functional inhibition of BCL2 significantly increased apoptosis induced by HH inhibition in DLBCL cells of both types. We also showed that DLBCL cells synthesize, secrete and respond to endogenous HH ligands, providing support for the existence of an autocrine HH signaling loop. Our findings provide novel evidence that dysregulation of HH pathway is involved in the biology of DLBCL and have significant therapeutic implications as they identify HH signaling as a potential therapeutic target in DLBCL, in particular for those lymphomas expressing the HH receptor smoothened.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults, accounting for 30-40% of cases of non-Hodgkin's lymphoma. 1 The pathogenesis of DLBCL is complex and heterogeneous, and many pathogenic mechanisms remain largely unknown. Gene expression profiling studies have distinguished three molecular subtypes of DLBCL known as germinal center (GC) B-cell type, activated B-cell (ABC) type and primary mediastinal large B-cell lymphoma (PMBL), which differ in cytogenetic and molecular features as well as in survival rates following chemotherapy. [2] [3] [4] [5] Although DLBCL has proven one of the most chemotherapy-responsive human malignancies, many (B50%) newly diagnosed patients will not be cured with conventional anthracycline-based chemotherapy. 1, 6 Therefore, new advances in the molecular pathogenesis of DLBCL are needed and they are expected to contribute to the development of new therapeutic approaches.
The initial observation of glioma-associated oncogene homologue (GLI) involvement in glioma development suggested the importance of hedgehog (HH) signaling in tumorigenesis. 7 Later, a definitive link between the HH pathway and cancer was established by the identification of heterozygote mutations affecting the HH receptor, Patched (PTC), and resulting in the abnormal activation of the HH pathway in basal cell carcinoma, rhabdomyosarcoma and neural tumors. 8 The HH signaling pathway is incompletely understood. The current paradigm of the 'canonical' pathway views HH signaling as a series of repressive interactions, which culminates in GLI-mediated transcriptional regulation of a variety of cellular processes. The HH family of proteins consists three distinct ligands, Sonic (SHH), Indian (IHH) and Desert (DHH), which appear to be processed by the same mechanism and use the same receptors and signal transduction pathway. 9 Briefly, HH ligands are processed intracellularly from a precursor peptide of B45 kDa to generate an N-terminal B20 kDa secreted peptide that is retained at or near the cell surface and a C-terminal 27 kDa glycosylated more diffusible peptide. 10 HH ligands interact with a receptor complex composed of two proteins, the 12 transmembrane protein, PTC, and the 7 transmembrane protein, smoothened (SMO). PTC is the HH ligand-binding subunit and SMO is the signal transduction component. In the absence of HH ligands, PTC inhibits SMO. Once HH binds PTC, this inhibition is released allowing SMO to transduce the HH signal, mediate by three five-zinc-finger transcription factors, GLI1, GLI2 and GLI3. 11 Although both GLI2 and GLI3 have transcriptional activation and repression properties, GLI1 is a strong positive regulator of HH transcriptional targets and is, itself, a transcriptional target of HH signaling. [12] [13] [14] [15] Although inappropriate activation of the HH signaling pathway has been shown in many cancers, 16 the assessment of the contribution of HH signaling pathway has not been thoroughly examined in hematologic malignancies. Recently, Dierks et al. 17 have shown that HH ligands secreted by bone marrow, nodal and splenic stromal cells function as survival factors for some B-cell lymphomas and plasma cell myeloma. More recently, Hegde et al. 18 have presented data further supporting the paracrine effect of HH signaling on the survival of low-grade B-cell lymphomas. We showed that HH signaling is activated in ALK-positive anaplastic large cell lymphoma cell lines and tumors and that selective inhibition of HH signaling pathway induced a significant decrease in cell viability due to apoptosis and cell-cycle arrest in ALK-positive anaplastic large cell lymphoma cell lines. 19 We have also investigated the expression of HH signaling proteins in a series of 67 DLBCL tumors and cells lines. 20 Our study results showed HH signaling proteins to be aberrantly expressed in DLBCL in comparison with lowgrade B-cell lymphomas and reactive lymph nodes. 20 Despite these important observations, a functional role of HH signaling in DLBCL has not been previously identified. Here, we show that inhibition of HH signaling results in cell-cycle arrest and apoptosis in DLBCL cells of GC type and ABC type, respectively. We also show that DLBCL cells synthesize, secrete and respond to endogenous HH ligands, providing evidence for the existence of an autocrine HH signaling loop in this aggressive lymphoma type.
Materials and methods

Cell lines
Twelve DLBCL cell lines were used; six GC type (BJAB, DOHH2, Pfeiffer, Toledo, SUDHL4 and SUDHL6), five ABC type (HBL1, OCI-LY3, OCI-LY10, SUDHL2 and U2932) and one PMBL cell line (U2940). DOHH2, SUDHL4 and U2940 were purchased from DSMZ (Germany), Pfeiffer, Toledo, and SUDHL6 were purchased from ATCC (Manassas, VA, USA), OCI-LY3 and OCI-LY10 were kindly provided by Michael G Rosenblum, MD Anderson Cancer Center and U2932, SUDHL2, BJAB and HBL1 were a generous gift from Felipe Samaniego, MD Anderson Cancer Center. All cell lines were maintained at 37 1C in RPMI 1640 (ATCC) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma, St Louis, MO, USA) in a humidified atmosphere containing 5% CO 2 . DOHH2, BJAB, Pfeiffer, SUDHL6, Toledo and SUDHL4 contain the t(14;18)(q32;q21) and are considered cell lines of DLBCL GC type. OCI-LY3, OCI-LY10, SUDHL2, U2932 and HBL1 lack the t(14;18) and were previously classified as ABC type. 2, [21] [22] [23] The human bone marrow stromal cell line HS-5 was purchased from ATCC.
Cell viability and clonogenicity assays, cyclopamine-KAAD, tomatidine, anti-HH antibody Cell viability assays were performed in RPMI with 2% FBS. A total of 20 Â 10 3 cells were treated with 5 and 10 mM of cyclopamine-KAAD (Calbiochem, San Diego, CA, USA), an inhibitor of SMO, and tomatidine (Calbiochem), an alkaloid similar to cyclopamine but lacking the capacity to inhibit SMO. After 48 h, cell viability was assessed using a cell proliferation kit, Cell Titer 96 Aqueous One Solution (MTS; Promega, Madison, WI, USA). Colony formation in methylcellulose (Stem Cell Technologies, Vancouver, BC, USA) was performed according to the manufacturer's instructions. A total of 500 cells were initially plated and incubated in 300 ml of methylcellulose (Stem Cell Technologies) with 10 mM of cyclopamine-KAAD, tomatidine and DMSO for 2 weeks. After 2 weeks wells were stained with p-iodonitrotetrazolium violet (Sigma) and the number of colonies was counted using a stereomicroscope. 5E1 anti-HH blocking antibody 24 was purchased from the Hybridoma Bank at the University of Iowa.
Non-neoplastic CD19 þ B-lymphoid cells and circulating CLL cells
Sorted CD19 þ B-lymphoid cells were collected from the peripheral blood of four healthy donors. They were plated in RPMI with 2% FBS and treated with cyclopamine-KAAD and tomatidine. Circulating chronic lymphocytic leukemia (CLL) cells were also collected from the peripheral blood of two patients (CLL1 and CLL2), plated in RPMI with 2% FBS. After 48 h, the culture medium was collected and used as controls for detection of secreted N-terminal HH.
Real-time quantitative (q) PCR and reverse transcriptase-PCR
Total RNA was extracted from the cell lines using RNeasy Minikit (Qiagen, Valencia, CA, USA) as per the manufacturer's protocol. cDNA synthesis was carried out using random primers and SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
The TaqMan minor groove binder probe and the ABI Prism 7900 HT Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA) were used for performing real-time PCR. The primers and probes for GLI1, CCND2, SHH, IHH, DHH and for an internal control gene, 18s rRNA, were obtained from PE Applied Biosystems. Each target was amplified individually and in duplicate. The relative levels of mRNA were calculated using DCT method. For reverse transcriptase (RT)-PCR of SMO, PTC, GLI1 and a-actin genes we used the primer sequences and PCR conditions previously described by Kobune et al. 25 
Western blot analysis
Western blotting was carried out as described previously. Transfection of GLI1-, GLI2-and HH-specific siRNAs sMART pool GLI1-, GLI2-, SHH-, IHH-specific and control siRNA mixtures were purchased from Dharmacon Inc (Lafayette, CO, USA). Transfections were performed by electroporation using the nucleofector transfection kit (Amaxa Biosystems, Gaithersberg, MD, USA) as per the manufacturer's instructions and as previously described. 19 Transfection of DOHH2 and BJAB was performed using the Nucleofector solution T and transfection of OCI-LY3 was performed using solution V (Amaxa Biosystems). Cells were harvested at 48 h after siRNA transfections and viability was tested by Trypan blue staining. Adequate inhibition of protein expression and mRNA levels was confirmed by western blot and q-PCR methods.
Apoptosis and cell-cycle analysis
Annexin V staining (BD Biosciences Pharmingen, San Jose, CA, USA) detected by flow cytometry was used to assess apoptosis according to the manufacturer's instructions. Cell-cycle analysis was performed using propidium iodide (PI). Approximately 1 Â 10 6 cells were collected, fixed, stained with PI in the presence of DNAse free RNAse (Sigma) and analyzed using flow cytometry. Inhibition of BCL2 function was performed using the BCL2 inhibitor YC137 (Calbiochem).
Detection of secreted HH proteins
The DLBCL cell lines, DOHH2, OCI-LY3, OCI-LY10 and Pfeiffer, the stromal cell line HS-5 and CLL cells (CLL1 and CLL2) were cultured in RPMI 1640 medium with 2% FBS for 48 h, after which media were collected and concentrated using Amicon Ultra centrifugal filter units (10K cutoff; Millipore, Billerica, MA, USA). Equal amounts of proteins from the media was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis-PAGE with 15% acrylamide gel, transferred onto polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA) and probed with an HH polyclonal antibody (H-160; Santa Cruz Biotechnology).
Results
Screening expression of HH signaling-related molecules in DLBCL cell lines Previously, we examined the expression of HH signaling-related proteins using immunohistochemistry and tissue microarrays in a series of 67 DLBCL tumors, 28 follicular lymphomas, 5 CLL/ small lymphocytic lymphoma (SLL) and 5 reactive benign lymph nodes. 20 We found that HH signaling proteins were strongly and frequently expressed in DLBCL and that these proteins were not expressed or weakly expressed in a subset of tumor cells in follicular lymphoma, CLL/SLL and non-neoplastic GC B-cells. 20 In DLBCL, SHH was expressed in 61 of 67 (91%) cases, GLI1 in 62 of 67 (93%) and GLI2 in 41 of 56 (73%). 20 Hence, we screened the expression of SMO, PTC and GLI1 by RT-PCR in 12 DLBCL cell lines of the three major molecular subtypes, GC type (BJAB, DOHH2, Pfeiffer, SUDLH4, SUDHL6 and Toledo), ABC type (HBL1, OCI-LY3, OCI-LY10, SUDHL2 and U2932) and PMBL (U2940). SMO was detected in nine DLBCL cells lines except for U2932, SUDHL6 and HBL1, and PTC and GLI1 were detected in all cell lines ( Figure 1a) . SMO is the target molecule for the HH inhibitor, cyclopamine, and GLI1 is a transcriptional effector of HH signaling. It has been shown that the constitutive activation of GLI1 promotes cancer development. 26, 27 Western blot analysis of representative DLBCL cell lines showed relatively high levels of GLI1 and GLI2 ( Figure 1b ) confirming our previous immunohistochemical results. 20 Low or no expression of GLI3 (not shown) was also observed. These results confirm the expression of HH signaling molecules in DLBCL. These findings raise the possibility that HH signaling has a role in the biology of DLBCL.
Inhibition of HH/GLI signaling using cyclopamine-KAAD results in decreased cell viability and colony formation in DLBCL cells
We next investigated whether inhibition of HH signaling decreased cell viability and clonogenicity of DLBCL cells. We used increasing concentrations of the SMO inhibitor, cyclopamine-KAAD, and as control we used tomatidine. Treating DLBCL cell lines with 5 mM and 10 mM cyclopamine-KAAD for 48 h resulted in a concentration-dependent decrease of cell viability in all of the SMO-positive DLBCL cell lines in comparison with tomatidine controls (Figures 1c and d) . In contrast, SUDHL6 and U2932 cells were not affected by cyclopamine, as both cell lines were negative for SMO (Figure 1c and d) . The decrease in cell viability induced by cyclopamine-KAAD was associated with a decrease in GLI1 mRNA levels indicating inhibition of HH signaling pathway ( Figure 1e ).
Cyclopamine-KAAD treatment of sorted non-neoplastic B lymphocytes collected from peripheral blood from four healthy donors showed no effect on cell viability further supporting that the cyclopamine effect on cell viability is not due to an unspecific toxic effect (Supplementary Figure 1A) . Previously, we also showed that cyclopamine-KAAD had no or little effect on the cell viability of cell lines with low levels of expression of HH and GLI proteins, such as Jurkat cells. 19 Long-term treatment of Pfeiffer, DOHH2 and OCI-LY3 with cyclopamine-KAAD (10 mM) for 2 weeks also resulted in decrease colony formation; an B80% (Pfeiffer), 75% (DOHH2) and a 65% (OCI-LY3) decrease in clonogenicity in comparison with controls (Supplementary Figure 1B ).
Silencing of GLI1 and GLI2 expression decreases cell viability in DLBCL
To further confirm that the decrease in cell viability was due to inhibition of HH signaling, we tested the effect of knocking down the expression of GLI1 and GLI2 by siRNA on cell viability. Nonspecific scrambled siRNA was used as a control. In DOHH2 cells, silencing GLI1 resulted in 22 and 38% decrease in cell viability at 24 and 48 h, respectively, compared with the control siRNA ( Figure 3a) . Treatment of SUDHL2 with 5 mM also resulted in increase of cells in sub-G 1 phase from 13.5 to 21.6%. Treatment of U2940 cells (PMBL cell line) with 5 mM cyclopamine-KAAD also resulted in an increase of the percentage of cells in sub-G 1 (from 4 to 27.5%) (Figure 3a) .
We assessed several cell-cycle regulatory proteins after treatment with cyclopamine-KAAD. Treatment of DOHH2 and BJAB cells with 5 mM of cyclopamine-KAAD for 24 h resulted in an increase in the expression of the cyclin-dependent kinase inhibitors p21 waf1 and p27 kip1 , which bind and inhibit kinase activities of cyclin-dependent kinase and block progression through G 1 /S restriction point, and in a decrease of the levels of cyclin D2 (indicator of progression through G 1 phase as well as a direct downstream target of HH signaling) (Figure 3b ). 28 Conversely, treatment of OCI-LY3 with 5 mM of cyclopamine-KAAD resulted in decrease of both p21 waf1 and p27 kip1 protein levels. In SUDHL2, similar treatment resulted in decrease of p27 kip1 and increased p21 waf1 levels. Treatment with cyclopamine-KAAD resulted in decreased cyclin D2 levels in both of these cell lines (Figure 3b The presence of significant apoptosis in the DLBCL cells of ABC type but not in those of GC type after treatment with cyclopamine-KAAD was further confirmed by cleavage of the poly(ADP-ribose) polymerase 1 (PARP1) enzyme. PARP1 is a nuclear enzyme of 116 kDa cleaved by activated caspase-3 and -7 to generate two fragments of 85 and 24 kDa when apoptosis occurs. 29 Treatment of DOHH2, Pfeiffer and BJAB cells with cyclopamine-KAAD for 24 h resulted in no cleavage of PARP1 (Figure 4b, upper panels) . However, similar treatment of OCI-LY3, OCI-LY10 and SUDHL2 resulted in cleavage of PARP1 (Figure 4b , lower panels).
BCL2/BAX ratio and modulation of BCL2 transcription by HH signaling inhibition contributes to the differences in apoptotic response among DLBCL subtypes
We investigated if BCL2 expression may explain the differences in the apoptotic rate observed between DLBCL subtypes after inhibition of HH signaling. We assessed the baseline levels of BCL2 and of its inhibitor, the proapoptotic protein, BAX in cell lines of the two subtypes of DLBCL. A ratio of BCL2/BAX ratio of equal to or higher than 1 was observed in DLBCL cells of GC type (BJAB, DOHH2 and Pfeiffer) in comparison to cells of ABC type (OCI-LY3, OCI-LY10 and SUDHL2), where this ratio was less than 1 ( Figure 5a ). As previous studies have shown that GLI1 and GLI2 are direct regulators of BCL2 gene transcription and HH overexpression results in upregulation of BCL2 protein levels, 30, 31 we also assessed the levels of BCL2 and BAX proteins after inhibiting HH/GLI signaling with cyclopamine-KAAD. Treatment with 5 mM cyclopamine-KAAD for 24 h resulted in a decrease of BCL2 protein levels in cell lines of ABC type (OCI-LY3, OCI-LY10 and SUDHL2) in comparison with the tomatidine controls, whereas no decrease of BCL2 protein levels was seen in cell lines of GC type (Figure 5b) . No appreciable change in the levels of BAX was observed after HH inhibition in most of the cell lines (Figure 5b ), except for BJAB cells, where a decrease of BAX protein levels was seen. Similar findings were obtained at the mRNA level; treatment with cyclopamine-KAAD resulted in marked decrease of BCL2 mRNA levels in cell lines of ABC type (OCI-LY3, OCI-LY10 and SUDHL2), whereas very little or no decrease was seen in cells of GC type (DOHH2 and BJAB) (Supplementary Figure 2A) . These findings suggest that the lack of BCL2 transcriptional modulation by HH inhibition in DLBCL of GC type may contribute to the resistance to apoptosis induced by cyclopamine.
To further investigate the contribution of BCL2 in protecting DLBCL cells of GC type from apoptosis induced by cyclopamine, we simultaneously treated DOHH2 cells with cyclopamine-KAAD and with the BCL2 inhibitor YC137. YC137 is a very specific and potent inhibitor of the antiapoptotic function of BCL2 that exerts its effect by disrupting its interaction with the BH3 domain of BID. 32 Simultaneous treatment of DOHH2 for 24 and 48 h with 5 mM of cyclopamine-KAAD and with 2.5 mM of YC137 resulted in increased levels of apoptosis (twofold) in comparison to treatments with cyclopamine-KAAD or YC137 alone ( Figure 5c, upper panel; Supplementary Figure 2B) . We also examined whether a combinational effect between YC137 and cyclopamine existed in additional cell lines, BJAB (GC type) and OCI-LY10 and SUDHL2 (ABC type). Cells were exposed to two concentrations of YC137 (0.1 and 0.5 mM) in combination with 5 mM cyclopamine and the effect on cell viability was studied by MTS assay. As shown in Figure 5c (lower panel) a synergistic effect was observed in those cell lines after exposure to cyclopamine and YC137. These results indicate a synergistic effect between HH and BCL2 inhibitors and suggest the possibility of using HH inhibitors in combination with BCL2 inhibitors as a potential therapeutic approach in DLBCL.
Expression of HH ligands (SHH, IHH and DHH) in DLBCL cell lines
We screened the expression of SHH, IHH and DHH in 12 DLBCL cell lines by q-PCR analysis. Eight cell lines (two GC type, BJAB and DOHH2, all ABC type and U2940 cells) expressed mRNAs for all three HH ligands. Three cell lines (SUDHL4, SUDHL6 and Toledo) had detectable mRNA levels of IHH and DHH but not SHH and one cell line (Pfeiffer) had detectable expression levels of DHH and SHH but no IHH (Figure 6a ). The detection of mRNA levels of HH ligands in most of the cell lines tested indicated that the DLBCL cells have the ability to synthesize HH ligands. Western blot analysis of four representative DLBCL cell lines, two GC and two ABC type using a polyclonal HH antibody (H160), capable of recognizing the N-terminal region of all three HH proteins, confirmed the presence of the HH precursor (B47 kDa) and of the processed N-terminal HH peptide (B23 kDa) in all four cell lines (Figure 6a, bottom left panel) . The presence of precursor and N-terminal SHH and IHH proteins was further confirmed using monoclonal antibodies specific for SHH (clone C9C5) and IHH (clone 187515), respectively (Figure 6a , bottom middle and right panels). SHH antibody does not cross-react with IHH or DHH and IHH antibody does not cross-react with SHH or DHH. Results showed that all the four cell lines synthesized SHH protein as evident by the appearance of distinct bands at B20 kDa and corresponding to the SHH N-terminal synthetic peptide (Figure 6a , bottom middle panel). Weak but distinct bands of SHH precursor were also seen in Pfeiffer and OCI-LY3. OCI-LY10 cells showed lower levels of the HH precursor form in comparison with other cell lines. The reason for these differences is not clear to us at this time. However, they may be dependent on the functionality of the intracellular processing machinery. Additional cell lines were also tested with the SHH and IHH monoclonal antibodies and the data are presented in Supplementary Figure 3 
DLBCL cells secrete N-terminal HH ligands that activate HH signaling providing evidence of an autocrine HH signaling loop in this lymphoma type
To test if HH ligands are also secreted by the neoplastic cells, we cultured 1 Â 10 6 cells in RPMI media with 2% FBS. After 48 h, the culture medium was collected, proteins were concentrated, and probed for the presence of N-terminal HH peptides. We found secreted N-terminal HH peptides in the culture medium collected from all the DLBCL cell lines analyzed (DOHH2, Pfeiffer, OCI-LY3 and OCI-LY10) and from the medium collected from the positive control, HS-5, but not from the media collected from cultured CLL cells (Figure 6b) . No HH precursor (full-length) band was detected in the media. These data indicate that DLBCL cells secrete HH ligands and raise the possibility of the existence of an autocrine HH signaling loop in this lymphoma type.
To test if secreted HH ligands activate HH signaling pathway, we silenced the expression of SHH and IHH with specific siRNA in DOHH2 and BJAB cells and after 48 h examined the effect on the levels of GLI1 mRNA (downstream target of HH signaling) by q-PCR. Silencing of SHH or IHH resulted in decreased levels of GLI1 mRNA in both the cell lines (Figure 6c) . Furthermore, incubation of DOHH2 cells with the standard blocking monoclonal antibody against HH, 5E1, 24 resulted in decreased in GLI1 and CCND2 mRNA levels within 5 h of treatment (Supplementary Figure 4) . Altogether, these results support the existence of an autocrine HH signaling loop in DLBCL.
Discussion
We previously showed high expression of HH signaling molecules in DLBCL tumors in comparison with low-grade B-cell lymphomas such as follicular lymphoma and CLL/SLL, as well as in comparison with non-neoplastic GC cells. 20 For this reason, we sought to explore the functional role of HH signaling in DLBCL. Here, we show that the HH signaling receptor components PTC and SMO are expressed in most of the DLBCL cell lines and that the HH transcriptional activator, GLI1, is expressed in all DLBCL cells that we screened. Inhibition of HH signaling pathway resulted in a decrease of cell viability, induced apoptosis, cell-cycle arrest and decreased clonogenicity in DLBCL cells. We also show that DLBCL cells secrete and respond to endogenous HH ligands providing support for the existence of an autocrine HH signaling loop in this lymphoma type.
Hedgehog signaling enhances tumor development by inducing proliferative and prosurvival signals. Gene expression profile studies have shown that GLI1 is mainly a transcriptional activator and is involved in the regulation of genes involved in cell-cycle control and/or cell proliferation including CYCLIN-D1, -D2 and -E1. 33, 34 GLI1 and GLI2 are also direct regulators of BCL2 gene transcription and HH overexpression results in upregulation of BCL2 protein levels, indicating that HH signal transduction leads to inactivation of apoptotic pathways. 30, 31, 35 Interestingly, we found that HH signaling inhibition with cyclopamine resulted predominantly in cell-cycle arrest in DLBCL cell lines of GC type and predominantly in apoptosis in those of ABC type. Cyclopamine treatment in DLBCL cells of ABC type induced apoptosis associated with a decrease in the expression of BCL2 and decrease in the BCL2/BAX ratio. However, no decrease in BCL2 expression or in the BCL2/BAX ratio was seen in DLBCL cells of GC type after treatment with similar concentrations of cyclopamine. We think that these differences in the modulation of BCL2 levels after HH inhibition in cells of GC and ABC subtype may be explained, at least in part, by loss of the usual transcriptional regulatory control of BCL2 in those DLBCL cell lines GC type carrying the t(14;18). This is further supported by our finding that cyclopamine decreased BCL2 mRNA levels in ABC type cells but caused very low or no change in the levels of BCL2 in GC type cells. In those DLBCL cell lines without t(14;18), BCL2 gene expression is under the control of its own promoter and thus under the usual transcriptional regulatory elements including HH signaling pathway. However, in those DLBCL cell lines with t(14;18), a functional BCL2 will be overexpressed mainly through transcriptional activation by the IgH regulatory elements, including the core enhancer (Em), independently of its own promoter and thus independently of GLI1 and GLI2 regulation. 36 Similarly, it has been found that the t(14;18) is one of the reasons behind the loss of the transcriptional repression of BCL2 by BCL6 in DLBCL. 37 Our experiments combining cyclopamine and the BCL2 inhibitor YC137 provide further evidence supporting that the levels of BCL2 expression are a factor in determining the susceptibility to apoptosis after inhibition of HH signaling, in particular in DLBCL of GC type. The mode of action of HH signaling in cancer in general appears to be rather complex and may be tumor dependent. Several studies suggest an autocrine action from HH signaling in some tumors and others favor a paracrine model. 38, 39 For example, a recent study indicates a role for HH signaling in the stroma, but not in the epithelial neoplastic cells, suggesting mainly a paracrine requirement for HH ligand (from tumor to stroma) in tumorigenesis of some epithelial cancers. 40 Another study showed that in pancreatic cancers, GLI transcription is decoupled from the upstream 'canonical' HH-PTC-SMO axis and that is regulated by other pathways and transcription factors such as TGF-b and K-RAS. 41 Sacedon et al. 42 have found that SHH is produced by follicular dendritic cells inside GC and that inhibition of SHH induces apoptosis in GC B cells, which is rescued by addition of SHH ligand, supporting that HH signaling has a paracrine role in the GC compartment. Other investigators have also shown that HH signaling has a paracrine role as a survival factor for low-grade B-cell neoplasms, including CLL/SLL and plasma cell myeloma. 17, 18 Using q-PCR analysis, we showed that most of the DLBCL cell lines have transcription of all the three HH ligands. Immunoblots detected the presence of both the HH precursor and the N-terminal peptide in cell lysates and secreted HH N-terminal peptide in the culture media supporting that HH ligands are synthesized and processed by DLBCL cells. Furthermore, our study also showed the existence of an autocrine HH signaling loop and that the 'canonical' HH-PTC-SMO axis is functional in DLBCL cells. We previously reported that tumor cells in lowgrade B-cell lymphomas are basically negative for HH ligands, 20 suggesting that in high-grade lymphomas, such as DLBCL, the gain of intracellular and cell-autonomous activation of the HH pathway represents an advantage for the tumor cells, allowing independence from the microenvironment.
The mechanism by which HH signaling is activated in DLBCL is not clear at this time. We and others 19, 43 provided evidence that activation of HH signaling pathway is enhanced by activation of PI3K/AKT pathway. Our preliminary data in DLBCL also support a direct synergism between PI3K/AKT and HH pathways (data not shown). It has been also shown that NF-kb regulates and contributes to SHH expression. 44, 45 Interestingly, we found that SHH mRNA was expressed in all the DLBCL cell lines of ABC type, which is associated with constitutive activation of NF-kb. 23 Additional mechanisms that may contribute to the activation of the HH signaling in DLBCL are possible and need to be explored. These include inactivating mutations of PTC, activation mutations of SMO and GLIs, gene amplifications or gains involving HH ligands, GLI1 and GLI2. 19, 40, [46] [47] [48] In summary, we have shown that HH signaling contributes to the biology of DLBCL and that inhibition of this signaling pathway interferes with proliferation and survival of DLBCL cells. These findings are of great interest because effective inhibitors of HH signaling are currently available and could form the basis of a novel therapeutic strategy in this lymphoma type.
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